Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors

• Unité de recherche: INNOSUISSE
• Numéro de projet: 120.434 IP-LS
• Titre du projet anglais: Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

Increased activity of mammalian target of rapamycin complex 1 (mTORC1) is linked to multiple disorders. We identified ten small compounds that selectively and efficiently inhibit mTORC1 in vitro with an innovative mode of action. We now aim to achieve preclinical proof of mechanism in mice.